About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

A new bone marrow test can help doctors predict risk of leukemia relapse The test might double survival rates by predicting a relapse up to three months earlier than standard care The test looks for ...

Identification of recurrent genetic abnormalities is important for disease evaluation, optimal risk stratification and treatment planning. Testing for recurrent genetic abnormalities should be ...

Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment ...

BOZEMAN, MT, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Alercell is all set to launch LENA Q51(R) in January 2023. A leukemia diagnostic test based on sequencing DNA will detect up to 51 Genes mutations in ...

Imbruvica plus venetoclax significantly extends PFS in untreated CLL patients compared to chlorambucil plus Gazyva, with 52 months versus 31 months. The combination therapy shows durable efficacy and ...

Leukemia is a blood cancer with abnormal white blood cell overproduction, affecting red blood cells and platelets, leading to anemia and infection risks. Diagnosis involves blood tests, bone marrow ...

The Test Before Treat campaign highlights how a patient’s genetic profile can change over time and encourages the use of a blood test to identify mutations to provide important insights into disease ...